

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Kiu Hung International Holdings Limited

僑雄國際控股有限公司

(Incorporated in the Cayman Islands with limited liability and continued in Bermuda with limited liability)

(Stock Code: 00381)

SUPPLEMENTAL ANNOUNCEMENT IN RESPECT OF ACQUISITION FRAMEWORK AGREEMENT

References is made to the announcements (the “**Announcements**”) of Kiu Hung International Holdings Limited (the “**Company**”) dated 4 November 2020 and 11 November 2020, in relation to the entering into of the Acquisition Framework Agreement in relation to the Possible Acquisition. Capitalised terms used herein shall have the same meanings as those defined in the Announcements unless otherwise specified.

LATEST INFORMATION ABOUT ACQUISITION FRAMEWORK AGREEMENT

To ensure a successful operation of the Company following completion of the possible acquisition, the Group will appoint Academician Xu Jianguo (徐建國) (“**Academician Xu**”) and Academician Zhao Kai (趙鎧) (“**Academician Zhao**”) as technical consultants of the project for the purposes of the management and operation of the Possible Acquisition. Remuneration of these technical consultants will be comprised of salary, share options, and more. Set forth below are detailed backgrounds of Academician Xu and Academician Xu:

Academician Xu

Xu Jianguo, an academician of Chinese Academy of Engineering, graduated from Shanxi Medical University, and later received a master’s degree in medicines from Chinese Academy of Medical Sciences, as well as a doctorate in medicines from Chinese Academy of Preventive Medicine* (中國預防醫學科學院醫學, currently known as Chinese Center for Disease Control and Prevention). He is also a medical microbiologist, and former director of National Institute for Communicable Disease Control and Prevention of Chinese Center for Disease Control and Prevention. Currently, Academician Xu serves as the director at the Sate Key Laboratory of Infectious Disease Prevention and Control, and an assistant director of the major science and technology special project headed “Prevention and Treatment of Major Infectious Diseases such as AIDS and Infectious Hepatitis”. In addition, he is also a chairman or member of various organizations, including chairman of the Second Biosecurity Expert Committee of National Pathogenic Microbiology Laboratory (第二屆國家病原微生物

實驗室生物安全專家委員會), chairman of the Biosecurity Industry Panel under the Third Laboratory Technology Committee of China National Accreditation Service for Conformity Assessment (國家認可委員會第三屆實驗室技術委員會生物安全專業委員會), member of Commission on Food Safety of the State Council, and member of the Second National Expert Committee of Animal Disease Prevention (第二屆全國動物防疫專家委員會). Furthermore, he also serves as an associate president of Chinese Society of Microbiology, as well as the president of The Chinese Pest Control Association.

Academician Zhao

Zhao Kai, an academician of Chinese Academy of Engineering, graduated from Fudan University. He is principally focused on the virology and vaccine research and development. In the 1960s, Academician Zhao led the research and development of vaccines for cell culture-derived smallpox, attenuated vaccines for rubella, and vaccines for blood-borne hepatitis B. He collaborated with Shanghai Institute of Biochemistry, Chinese Academy of Sciences on the research and development of the hepatitis B vaccine (based on recombinant vaccinia virus), and subsequently introduced the production technology of hepatitis B vaccine (based recombinant yeast) from Merck & Co., Inc, an American company. As a result, the quality and quantity of vaccine production continues to improve so as to meet the vaccination requirements of newborns for hepatitis B immunization. In the 21st century, Academician Zhao participated in and completed the mechanism research on antigen-antibody complex immunotherapy for hepatitis B virus infection, as well as the first innovative research on effective prevention and control of the H1N1 influenza pandemic and its integration in the PRC. The aforesaid scientific research achievements received various awards, including three first prizes of State Science and Technology Progress Award, three first prizes of Ministerial Science and Technology Progress Award, one first prize of Ministerial Natural Science Award, and three new drug certificates. Furthermore, Academician Zhao is also an editor in chief for four monographs and an assistant editor for ten monographs, respectively.

SUPPLEMENTAL INFORMATION OF TARGET COMPANY

Set forth below is an update on the team members of the Target Company:

Full Name	Position/ Academic Status	Achievements and Honors	Responsibility
Yuelong Shu (舒躍龍)	Researcher, and doctor	He is the dean of School of Public Health (Shenzhen), Sun Yat-sen University, and holds titles in other organizations, including deputy director of WHO Collaborating Centre for Surveillance, Research and Training of Emerging Infectious Diseases, chairman of Asia-Pacific Alliance for the Control of Influenza, and editor in chief of Chinese Journal of Virology. Previously, he served as deputy director of the National Institute for Viral Disease Control and Prevention, China CDC, the director of the Chinese National Influenza Center, and director of WHO Collaborating Centre for Reference and Research on Influenza. He has long focused on research of influenza etiology and epidemiology, and published more than 300 academic papers, among which, he published over 100 papers as the correspondence (common correspondence) author in various academic journals, including Science, Nature, NEJM, and Lancet. His research achievements were included to the 2013 Top Ten Advancements in Science of China, and received the special prize in State Science and Technology Progress Award. Besides being a receiver of the National Science Fund for Distinguished Young Scholars and China Youth Science and Technology Award, Professor Yuelong Shu is part of the first science and technology innovation leaders under the national “Ten Thousand Talent Program” and 2014 China Top Ten Technological Innovators.	Chief technology officer

Full Name	Position/ Academic Status	Achievements and Honors	Responsibility
Ma Xuejun (馬學軍)	Researcher, and doctor	In 1999, he received a PhD degree in Science from the National Key Laboratory of Genetic Engineering in Virus*, National Institute for Viral Disease Control and Prevention, China CDC (中國疾病預防控制中心病毒預防控制所病毒基因工程國家重點實驗室) upon graduation. He acts as the executive director of China Technology Innovation Alliance of In Vitro Diagnostic Industry* (中國體外診斷產業技術創新戰略聯盟), the standing committee member of Travel Health Professional Committee of Chinese Preventive Medicine Association* (中華預防醫學會旅行衛生專業委員會), the deputy head of Pathogen Diagnostic Reagents Team under the Professional Committee on the Etiology of Zoonoses, Chinese Society for Microbiology* (中國微生物學會人獸共患病病原學專業委員會病原診斷試劑學組) and the standing committee member of Biological Diagnostic Technology Branch, China Medicinal Biotechnology Association* (中國醫藥技術協會生物診斷技術分會).	Technical consultant
Yuan Yi (袁嫻)	Associate researcher, and doctor	She is a doctor in biology at School of Life Sciences, Tsinghua University, and serves as an assistant researcher in nano-oncology at the National Center for Nanoscience and Technology, Chinese Academy of Sciences. Furthermore, she is a postdoctoral researcher at Chinese Center for Disease Control and Prevention.	Pharmacology and toxicology
Liu Junmin (劉俊敏)	Bachelor	He is a holder of a bachelor's degree in economics of Guangzhou University, and engaged in business risk control management for a long time.	Legal advisor

Full Name	Position/ Academic Status	Achievements and Honors	Responsibility
Zheng Lishu (鄭麗舒)	Researcher, and doctor	She is a researcher at the National Institute for Viral Disease Control and Prevention, China CDC. Currently, she is mainly engaged in the research and development of genetic engineering drugs and vaccines, as well as the epidemiological research of common and respiratory viruses and related basic research.	Pharmacodynamics research
Zhang Jiaying (張佳瑩)	Master	She is a holder of a bachelor's degree in accounting and a master's degree in management from Huazhong University of Science and Technology, and works in Ruihua Certified Public Accountants, providing financial and auditing services for the large enterprises such as State Grid. Furthermore, she participates in IPO and NEEQ projects as well as internal audit for the subsidiaries of Top 500 Companies.	Chief financial officer
Liu Li (劉莉)	Master	She received a MBA degree from Marshall School of Business, University of Southern California. Currently, she is a licensed person with the Securities and Futures Commission of Hong Kong for Type 1 and Type 6, with over 10 years of experience in the international private equity, securities and fixed services in top four accounting firms.	Investor relations advisor

The above information is supplemental to information as contained in the Announcements.

Academician Xu and Academician Zhao were introduced to our Group by Mr. Hou Yunde, an independent non-executive Director. Mr. Hou Yunde has been engaged in the research of medical virology for over 50 years and has made outstanding achievements in research and development of molecular virology, genetically engineered interferon and other genetic drugs, as well as in the control of emerging infectious diseases in China. He has made outstanding contributions to the industrialization of medical molecular virology, genetic engineering and biotechnology, as well as the control of infectious diseases in China. During the outbreak of new H1N1 pandemic in 2009, as the head of the Joint Prevention and

Control Mechanism Expert Committee* (聯防聯控機制專家委員會), Mr. Hou Yunde, through collaborative innovation with renowned scientists across the country by using the national systems, succeeded in man-made intervention against an influenza pandemic for the first time in the history of mankind and gained international recognition. He has published more than 400 papers and nine major works at home and abroad. Mr. Hou Yunde has won various awards, including 2 first prizes and 7 second prizes of State Science and Technology Progress Award, 2 second prizes of State Natural Science Award, 1 third prize of the National Technology and Innovation Awards, 10 first prizes of Science and Technology Achievement Award of the National Health Commission of the PRC, and 7 National New Drug Certificates. Previously, he received the Ho Leung Ho Lee Award, and China Medical Science Award* (中國醫學科學獎). Mr. Hou Yunde was elected as a member of the Chinese Academy of Engineering in 1994 and served as the deputy president of the Chinese Academy of Engineering.

By Order of the Board
Kiu Hung International Holdings Limited
Zhang Qijun
Chairman

Hong Kong, 19 November 2020

As at the date of this announcement, the Board comprises three executive Directors, Mr. Zhang Qijun, Mr. Chen Jian and Mr. Liu Mingqing and six independent non-executive Directors, Mr. Hou Yunde, Mr. Wang Xiao Ning, Mr. Cheng Ho On, Mr. Kong Chun Wing, Mr. Lai Chi Yin, Samuel and Ms. Chen Yuxin.